Поиск
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.

Список литературы

  1. Лукина Е.А. Болезнь Гоше: современная диагностика и лечение. Клиническая онкогематология, 2009; 2(2):196–199
  2. Baldellou A., Andria G., Campbell P.E. et al. Paediatric nonneuronopathic Gaucher disease: recommendations for treatment and monitoring. Eur J Pediatr, 2004; 163: 67–75.
  3. Stone DL, Tayebi N, Orvisky E, Stubblefield B, Madike V, Sidransky E. Glucocerebrosidase gene mutations in patients with type 2 Gaucher disease. Human Mutation, 2000; 15(2): 181–188. doi:10.1002/(sici)1098-1004(200002)15:2<181::aid-humu7>3.0.co;2-s
  4. Do J., McKinney C., Sharma P., Sidransky E. Glucocerebrosidase and its relevance to Parkinson disease. Mol Neurodegener. 2019 Aug 29;14(1):36. doi: 10.1186/s13024-019-0336-2.
  5. Краснопольская К.Д. Наследственные болезни обмена веществ. Справочное пособие для врачей. М.: Фохат; 2005; 364 с.
  6. Zimran A., Wajnrajch M., Hernandez B., Pastores G.M. Taliglucerase alfa: safety and efficacy across 6 clinical studies in adults and children with Gaucher disease. Orphanet Journal of Rare Diseases, 2018 Feb; 23:13(1): 36
  7. Букина Т.М. Биохимическая и молекулярно-генетическая характеристика болезни Гоше у российских пациентов: дис. канд. биол. наук: 3.00.15. М.;2005; 114 с.
  8. Grabowski G., Zimran A., Ida H. Gaucher disease types 1 and 3: Phenotypic characterization of large populations from the ICGG Gaucher Registry. Am J Hematol, 2015; 90(1): 12–18
  9. Nalysnyk L., Rotella P., Simeone J. et al. Gaucher disease epidemiology and natural history: a comprehensive review of the literature. Hematology, 2017; 22(2): 65–73.
  10. Bodamer O., Hung C. Laboratory and genetic evaluation of Gaucher disease. Wiener Medizinische Wochenschrift, 2010; 160(23-24): 600–604
  11. Sibille A., Eng C., Kim S. et al. Phenotype/genotype correlations in Gaucher disease type 1: clinical and therapeutic implications. Am J Hum Genet. 1993; 52(6): 1094–1101
  12. Sidransky E., Bottler A., Stubblefield B., Ginns E. DNA mutational analysis of type 1 and type 3 Gaucher patients: How well do mutations predict phenotype? Hum Mutat, 1994; 3(1): 25–28
  13. Grabowski G. Gaucher disease and other storage disorders. Hematology Am Soc Hematol. Educ Program, 2012; 8(1): 13–18
  14. Revel-Vilk S., Szer J., Mehta A., Zimran A. How we manage Gaucher Disease in the era of choices. Br J Haematol, 2018; 182: 467–480
  15. Мовсисян Г.Б. Оптимизация оказания медицинской помощи детям с болезнью Гоше в Российской Федерации. Автореф. канд. мед. наук. М., 2018
  16. Vellodi A., Bembi B., de Villemeur T.B. et al. Management of neuronopathic Gaucher disease: a European consensus. J Inherit Metab Dis, 2001; 24: 319–327
  17. Pastores G.M., Weinreb N.J., Aerts H. et al. Therapeutic goals in the treatment of Gaucher disease. Semin Hematol, 2004; 41(4 Suppl 5): 4–14
  18. Charrow J., Esplin J.A., Gribble T.J. et al. Gaucher disease: recommendations on diagnosis, evaluation, and monitoring. Arch Intern Med, 1998; 158: 1754–1760
  19. Grabowski G.A., Andria G., Baldellou A. et al.  Pediatric nonneuronopathic Gaucher disease: presentation, diagnosis and assessment. Consensus statements. Eur J Pediatr, 2004;163: 58–66
  20. Kaplan P., Andersson H., Kacena K., Yee J. The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis. Arch Pediatr Adolesc Med, 2006; 160(6): 603–608
  21. Bultron G., Kacena K., Pearson D. et al. The risk of Parkinson’s disease in type 1 Gaucher disease. J Inherit Metab Dis, 2010; 33(2): 167–173
  22. Pastores G., Barnett N., Bathan P., Kolodny E. A neurological symptom survey of patients with type I Gaucher disease. J Inherit Metab Dis, 2003; 26(7): 641.
  23. Huang W, Zhang X, Chen W. Gaucher disease: a lysosomal neurodegenerative disorder. Eur Rev Wed Pharmocol Sci, 2015; 19(7): 1219–1226
  24. Tylki-Szymanska A., Vellodi A., El-Beshlawy A., Cole J., Kolodny E. Neuronopathic Gaucher disease: demographic and clinical features of 131 patients enrolled in the International Collaborative Gaucher Group Neurological Outcomes Subregistry. J Inherit Metab Dis, 2010; 33(4): 339–346
  25. Rosenbloom B., Weinreb N. Gaucher Disease: A Comprehensive Review. Crit Rev Oncog, 2013; 18(3): 163–175
  26. Weinthal J.A. Prognosis of patients with Gaucher disease. Clin Adv Hematol & Oncol, 2012;10(6):10–11.
  27. Kallish S., Kaplan P. A disease severity scoring system for children with type 1 Gaucher disease. Eur J Pediatr. 2013 Jan;172(1):39–43. doi: 10.1007/s00431-012-1830-5.
  28. Hadas-Halpern I., Deeb M., Abrahamov A. et al. Gaucher disease: spectrum of sonographic findings in the liver. J Ultrasound Med, 2010; 29(5): 727–733
  29. Miller A., Brown L.K., Pastores G.M. et al. Pulmonary involvement in type 1 Gaucher disease: functional and exercise findings in patients with and without clinical interstitial lung disease. Clin Genet 2003; 63: 5: 368–376
  30. Andrade-Campos M., Alfonso P., Irun P. et al. Diagnosis features of pediatric Gaucher. Orphanet Journal of Rare Diseases, 2017; May 3;12(1):84
  31. Carubbi F., Cappellini M.D., Fargion S. Fracanzani A.L., Nascimbeni F. Liver involvement in Gaucher disease: A practical review for the hepatologist and the gastroenterologist. Digestive and Liver Disease, 2020;52: 368–373
  32. Hughes D., Sidransky E. Gaucher disease: Initial assessment, monitoring, and prognosis https://www.uptodate.com/contents/gaucher-disease-initial-assessment-monitoring-and-prognosis (last updated: Aug 28, 2021)
  33. Giraldo P., Andrade-Campos M. Novel Management and Screening Approaches for Haematological Complications of Gaucher"s Disease. J Blood Med. 2021 Dec 7;12:1045-1056. doi: 10.2147/JBM.S279756.
  34. Stein P., Yang R., Liu J., Pastores G.M., Mistry P.K. Evaluation of high density lipoprotein as a circulating biomarker of Gaucher disease activity. J Inherit Metab Dis, 2011; 34(2): 429–437
  35. Wine E.,Yaniv I., Cohen I. Hyperimmunoglobulinemia in pediatric-onset type 1 Gaucher disease and effects of enzyme replacement therapy. J Pediatr Hematol Oncol, 2007; 29(7): 451–457
  36. Mekinian A., Stirnemann J., Belmatoug N. et al. Ferritinemia during type 1 Gaucher disease: Mechanisms and progression under treatment. Blood Cells, Molecules, and Diseases, 2012;49(1): 53–57.
  37. Motta I, Consonni D, Stroppiano M, Benedetto C, Cassinerio E, Tappino B, Ranalli P, Borin L, Facchini L, Patriarca A, Barcellini W, Lanza F, Filocamo M, Cappellini MD; Splenomegaly Gaucher group. Predicting the probability of Gaucher disease in subjects with splenomegaly and thrombocytopenia. Sci Rep. 2021 Jan 28;11(1):2594, Stein P, Yu H, Jain D, Mistry PK. Hyperferritinemia and iron overload in type 1 Gaucher disease. Am J Hematol. 2010 Jul;85(7):472-6.
  38. Regenboog M., van Kuilenburg A.B., Verheij J., Swinkels D.W., Hollak C.E. Hyperferritinemia and iron metabolism in Gaucher disease: Potential pathophysiological implications. Blood Rev. 2016 Nov;30(6):431–437. doi: 10.1016/j.blre.2016.05.003.
  39. Mikosch P., Reed M., Baker R. et al. Changes of bone metabolism in seven patients with Gaucher disease treated consecutively with imiglucerase and miglustat. Calcif Tissue Int. 2008 Jul;83(1):43-54. doi: 10.1007/s00223-008-9143-4.
  40. Ioscovich A., Fadeev D., Kenet G., Naamad M., Schtrechman G., Zimran A., Elstein D. Thromboelastography as a Surrogate Marker of Perisurgical Hemostasis in Gaucher Disease. Clin Appl Thromb Hemost. 2016 Oct;22(7):693–697. doi: 10.1177/1076029615578165.
  41. Deghady A., Marzouk I., El-Shayeb A., Wali Y. Coagulation abnormalities in type 1 Gaucher disease in children. Pediatr Hematol Oncol, 2006; 23(5): 411–417.
  42. Stroppiano M., Calevo M., Corsolini F. et al. Validity of β-D-glucosidase activity measured in dried blood samples for detection of potential Gaucher disease patients. Clin Biochem, 2014; 47(13-14): 1293–1296
  43. Rolfs A., Giese A., Grittner U. et al. Glucosylsphingosine is a highly sensitive and specific biomarker for primary diagnostic and follow-up monitoring in Gaucher disease in a non-Jewish, Caucasian cohort of Gaucher disease patients. PLoS One, 2013; 8(11): e79732
  44. Murugesan V., Chuang W.L., Liu J. et al. Glucosylsphingosine is a key biomarker of Gaucher disease. Am J Hematol. 2016 Nov;91(11):1082-1089. doi: 10.1002/ajh.24491.
  45. Aerts J.M., van Breemen M., Bussink A. et al. Biomarkers for lysosomal storage disorders: identification and application as exemplified by chitotriosidase in Gaucher disease. Acta Paediatr, 2008; 97: 7-14.
  46. Мазырко Е.В., Ростовцев М.В., Коробкин А.В. Болезнь Гоше. Опыт рентгенодиагностики поражения скелета. Медицинская визуализация, 2010; №2: 48–53
  47. Faden M., Krakow D., Ezgu F. et al. The Erlenmeyer flask bone deformity in the skeletal dysplasias. Am J Med Genet Part A, 2009; 149A(6): 1334–1345
  48. Maas M., Hangartner T., Mariani G. et al. Recommendations for the assessment and monitoring of skeletal manifestations in children with Gaucher disease. Sceletal Radiol, 2008;37(3): 185–188.
  49. van Dahl S, Poll L, Di Rocco M. Evidence-based recommendations for monitoring bone disease and the response to enzyme replacement therapy in Gaucher patients. Curr Med Res Opin, 2006; 22(6): 1045–1064.
  50. Rosenthal D.I., Mayo-Smith W., Goodsitt M.M., Doppelt S., Mankin H.J. Bone and bone marrow changes in Gaucher disease: evaluation with quantitative CT. Radiology. 1989 Jan;170(1 Pt 1):143–146. doi: 10.1148/radiology.170.1.2909087.
  51. Скрипникова И.А., Щеплягина Л.А., Новиков В.Е. и др. Возможности костной рентгеновской денситометрии в клинической практике. М.: ФГБУ «ГНИЦПМ»; 2015; 36 с.
  52. Giuffrida G., Cappellini M., Carubbi F. et al. Management of bone disease in Gaucher disease type 1: clinical practice. Adv Ther, 2014; 31(12): 1197–1212.
  53. Hollak C., van Weely S.,van Oers M., Aerts J. Marked elevation of plasms chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest, 1994; 93(3): 1288–1292.
  54. Rizk TM, Ariganjoye RO, Alsaeed GI. Gaucher disease. Unusual presentation and mini-review. Neurosciences (Riyadh). 2015 Jul;20(3):271-6.
  55. Félix PintoEma Nassone Muhammad Ismail Astrilde JamisseFrancyne KubaskiAna Carolina Brusius-Facchin Roberto Giugliani Luís MadeiraFabíola Fernandes Difficulties in the Diagnosis of Gaucher Disease in a Low-Income Country: A Case Report from Mozambique J. inborn errors metab. screen. 9;2021; https://doi.org/10.1590/2326-4594-JIEMS-2020-0022.
  56. Wajiha Maan, Manoochehr Karjoo, Mirza Beg Report of Four Children with Gaucher Disease and Review of Literature Int J Pediatr, Vol.4, N.8, Serial No.32, Aug 2016.
  57. Poffenberger C.N., Inati S., Tayebi N. et al. EEG abnormalities in patients with chronic neuronopathic Gaucher disease: A retrospective review. Mol Genet Metab. 2020 Nov;131(3):358-363. doi: 10.1016/j.ymgme.2020.10.010
  58. Weinreb NJ, Goker-Alpan O, Kishnani PS, Longo N, Burrow TA, Bernat JA, Gupta P, Henderson N, Pedro H, Prada CE, Vats D, Pathak RR, Wright E, Ficicioglu C. The diagnosis and management of Gaucher disease in pediatric patients: Where do we go from here? Mol Genet Metab. 2022 May;136(1):4-21. doi: 10.1016/j.ymgme.2022.03.001. Epub 2022 Mar 9. PMID: 35367141.
  59. Vellodi A., Tylki-Szymanska A., Davies E.H. et al. Management of neuronopathic Gaucher disease: revised recommendations. J Inherit Metab Dis. 2009 Oct;32(5):660-664. doi: 10.1007/s10545-009-1164-2.
  60. Alaei M.R., Tabrizi A., Jafari N., Mozafari H. Gaucher Disease: New Expanded Classification Emphasizing Neurological Features. Iran J Child Neurol. 2019 Winter;13(1):7–24.
  61. Altunbas G., Ercan S., Inanç I.H. et al. Extensive vascular and valvular involvement in Gaucher disease. Asian Cardiovasc Thorac Ann. 2015 May;23(4):446-8. doi: 10.1177/0218492313513598.
  62. Kishnani PS, Al-Hertani W, Balwani M, Göker-Alpan Ö, Lau HA, Wasserstein M, Weinreb NJ, Grabowski G. Screening, patient identification, evaluation, and treatment in patients with Gaucher disease: Results from a Delphi consensus. Mol Genet Metab. 2022 Feb;135(2):154-162.
  63. Мовсисян Г.Б., Сурков А.Н., Намазова-Баранова Л.С., Савостьянов К.В. Особенности диагностики болезни Гоше у детей в Российской Федерации. Российский журнал детской гематологии и онкологии 2020;7(2):42–53.
  64. Hughes DA, Pastores GM. Gaucher Disease. 2000 Jul 27 [updated 2023 Dec 7]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024. PMID: 20301446
  65. Dinur T, Bauer P, Beetz C, Kramp G, Cozma C, Iurașcu MI, Becker-Cohen M, Istaiti M, Rolfs A, Zimran A, Revel-Vilk S. Gaucher Disease Diagnosis Using Lyso-Gb1 on Dry Blood Spot Samples: Time to Change the Paradigm? Int J Mol Sci. 2022 Jan 30;23(3):1627. doi: 10.3390/ijms23031627. PMID: 35163551; PMCID: PMC8835963
  66. Kaplan P., Baris H., De Meirleir L. et al. Revised recommendations for the management of Gaucher disease in children. Eur J Pediatr, 2013 Apr;172(4):447–458
  67. van Dahl S., Mengel E. Lysosomal storage diseases as differential diagnosis of hepatosplenomegaly. Best Practice & Research Clinical Gastroenterology, 2010; 24(5): 619–628.
  68. Marcucci G., Zimran A., Bembi B. et al. Gaucher disease and bone manifestations. Calcif Tissue Int, 2014; 95(6): 477–494.
  69. Интернет ресурс: https://rarediseases.org/rare-diseases/gaucher-disease/
  70. Leonart LP, Fachi MM, Böger B, Silva MRD, Szpak R, Lombardi NF, Pedroso MLA, Pontarolo R. A Systematic Review and Meta-analyses of Longitudinal Studies on Drug Treatments for Gaucher Disease. Ann Pharmacother. 2022 Jul 11:10600280221108443
  71. Goker-Alpan O. Optimal therapy in Gaucher disease. Ther Clin Risk Manag, 2010;6: 315–323.
  72. Starzyk K., Richards S., Yee J. et al. The long-term international safety experience of imiglucerase therapy for Gaucher disease. Mol Genet Metab. 2007; 90(2): 157–163
  73. Инструкция к лекарственному препарату: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?idReg=10644&t=
  74. Weinreb N.J., Goldblatt J., Villalobos J. et al. Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment. J Inherit Metab Dis, 2013 May;36(3):543–53.
  75. Инструкция к лекарственному препарату: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?idReg=36175&t=
  76. Gonzalez D.E., Turkia H.B., Lukina E.A. et al. Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double-blind, multinational, Phase 3 study. Am J Hematol, 2013;88: 166–171. doi: 10.1002/ajh.23381
  77. Pastores G.M., Rosenbloom B., Weinreb N. et al. A multicenter open-label treatment protocol (HGT-GCB-058) of velaglucerase alfa enzyme replacement therapy in patients with Gaucher disease type 1: safety and tolerability. Genetics in Medicine. 2014;16(5):359–366. doi:10.1038/gim.2013.154.
  78. Giraldo P. et al. Safety and efficacy of velaglucerase alfa in children with type 1 Gaucher disease: 2-year experience. Poster presented at the American College of Medical Genetics (ACMG) Annual Clinical Genetics Meeting. Charlotte, North Carolina, USA. 2012, March 27–31.
  79. Azza A. G. Tantawy, MD, Amal El-Beshlawy, MD, Iman Marzouk, MD et al. Results From a 12-Month Open-Label Phase 1/2 Study of Velaglucerase Alfa in Children and Adolescents With Type 3 Gaucher Disease. Journal of Inborn Errors of Metabolism & Screening 2018, Volume 6: 1–5https://doi.org/10.1177/2326409818765564
  80. Sagara R, Ishigaki M, Otsuka M, Murayama K, Ida H, Fernandez J. Long-term safety and effectiveness of velaglucerase alfa in Gaucher disease: 6-year interim analysis of a post-marketing surveillance in Japan. Orphanet J Rare Dis. 2021 Dec 4;16(1):502
  81. Инструкция к лекарственному препарату: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=40906850-0018-4a7e-b9e1-21ab4ff89194&t=
  82. Zimran A. et al. Taliglucerase alfa: safety and efficacy across 6 clinical studies in adults and children with Gaucher disease. Orphanet Journal of Rare Diseases, 2018 Feb; 23:13(1):36
  83. Zimran A, Gonzalez-Rodriguez DE, Abrahamov A, Elstein D, Paz A, Brill-Almon E, Chertkoff R. Safety and efficacy of two dose levels of taliglucerase alfa in pediatric patients with Gaucher disease. Blood Cells Mol Dis. 2015 Jan;54(1):9-16. doi: 10.1016/j.bcmd.2014.10.002.
  84. Hughes D, Mikosch P, Belmatoug N, Carubbi F, Cox T, Goker-Alpan O, Kindmark A, Mistry P, Poll L, Weinreb N, Deegan P. Gaucher Disease in Bone: From Pathophysiology to Practice. J Bone Miner Res. 2019 Jun;34(6):996-1013
  85. Gaucher Disease GeneReviews® [Internet]. https://www.ncbi.nlm.nih.gov/books/NBK1269/ Gregory M Pastores, MD and Derralynn A Hughes, MA, DPhil, FRCP, FRCPath Initial Posting: July 27, 2000; Last Update: June 21, 2018, Kaplan P, Baris H, De Meirleir L, Di Rocco M, El-Beshlawy A, Huemer M, Martins AM, Nascu I, Rohrbach M, Steinbach L, Cohen IJ. Revised recommendations for the management of Gaucher disease in children. Eur J Pediatr. 2013 Apr;172(4):447-58.
  86. Bembi В., Ciana G., Mengel E. et al. Bone complications in children with Gaucher disease. Br J Radiol 2002;75(1):37–43.
  87. Goker-Alpan O. Therapeutic approaches to bone pathology in Gaucher disease: past, present and future. Mol Genet Metab. 2011 Dec;104(4):438-47. doi: 10.1016/j.ymgme.2011.08.004. Epub 2011 Aug 11. PMID: 21889384.
  88. Kishnani P.S., Al-Hertani W., Balwani M. et al. Screening, patient identification, evaluation, and treatment in patients with Gaucher disease: Results from a Delphi consensus. Mol Genet Metab. 2022 Feb;135(2):154–162. doi: 10.1016/j.ymgme.2021.12.009
  89. Accordant Health Services: CVS Caremark. Exercise and Gaucher Disease.fckLR http://www.cvscaremarkspecialtyrx.com/patients/condition-resources-tools/lysosomal-storage-disorders/gaucher-disease/staying-healthy/exerc. Updated April 30, 2010. Accessed April 1, 2011
  90. Marzouk I., Deghady A., Omar O.M., Ashour R.S. Hyperimmunoglobulinemia and IgG Subclass Abnormalities in Children With Gaucher Disease. J Pediatr Hematol Oncol. 2019 Oct;41(7):e416–e420. doi: 10.1097/MPH.0000000000001574
  91. Puri R.D., Kapoor S., Kishnani P.S. et al. Gaucher Disease Task Force. Diagnosis and Management of Gaucher Disease in India — Consensus Guidelines of the Gaucher Disease Task Force of the Society for Indian Academy of Medical Genetics and the Indian Academy of Pediatrics. Indian Pediatr. 2018 Feb 15;55(2):143–153.
  92. Prevention of infection in patients with impaired splenic function https://www.uptodate.com/contents/prevention-of-infection-in-patients-with-impaired-splenic-function?topicRef=3994&source=see_link (last updated: Jan 20, 2022), Gaucher disease National Diagnosis and Treatment Protocol 2007 (www.has-sante.fr)
  93. Pasternack M.S., D.Spelman D., Edwards M.S. Prevention of infection in patients with impaired splenic function https://www.uptodate.com/contents/prevention-of-infection-in-patients-with-impaired-splenic-function?sectionName=VACCINATIONS&search=%D0%B2%D0%B0%D0%BA%D1%86%D0%B8%D0%BD%D0%B0%D1%86%D0%B8%D1%8F%20%D0%B3%D0%BE%D1%88%D0%B5&topicRef=117640&anchor=H3543384193&source=see_link#H3543384193 (last updated jan 20, 2022).
  94. Stirnemann J., Belmatoug N., Camou F. et al. A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments. Int J Mo. Sci, 2017; 18: 441
  95. Сметанина Н.С. Гематологические проявления болезни Гоше. Вопросы гематологии/онкологии и иммунопатологии в педиатрии, 2016;15(2):53–58.
  96. Bohte A., van Dussen L., Akkerman E. et al. Liver fibrosis in type I Gaucher disease: magnetic resonance imaging, transient elastography and parameters of iron storage. PLoS One, 2013; 8(3): e57507
  97. de Lédinghen V., Le Bail B., Rebouissoux L. et al. Liver Stiffness Measurement in Children Using FibroScan: Feasibility Study and Comparison With Fibrotest, Aspartate Transaminase to Platelets Ratio Index, and Liver Biopsy. J Pediatr Gastroenterol Nutr, 2007; 45(4):443-450
  98. Мовсисян Г.Б. Оптимизация оказания медицинской помощи детям с болезнью Гоше в Российской Федерации. канд. мед. наук: 14.01.08 / Автор Мовсисян Гоар Борисовна. — М., 2018. — 185 с. — Библиогр.: 169–185
  99. Кривенцова Н.А., Терещенко Г.В. Вопросы гематологии/онкологии и иммунопатологии в педиатрии, 2023; 22 (1): 73–7. DOI: 10.24287/1726-1708-2023-22-1-73-77.
  100. Gawad Tantawy A.A., Moneam Adly A.A., Madkour S.S., Salah El-Din N.Y. Pulmonary manifestations in young Gaucher disease patients: Phenotype-genotype correlation and radiological findings. Pediatr Pulmonol. 2020 Feb;55(2):441–448. doi: 10.1002/ppul.24544.

Для продолжения работы требуется Регистрация
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Оглавление

Данный блок поддерживает скрол*